European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

  • Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved in Europe for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer

  • Tecentriq combination improved overall survival and progression-free survival compared with the previous standard of care

Basel, 2 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re delighted that people in Europe can now benefit from this combination and we look forward to working with individual countries within the EU to ensure people can access the combination as soon as possible.”

“The results of the IMbrave150 study mark a breakthrough in the treatment of advanced liver cancer, one of the few cancers with a rising death rate and limited options in the first-line setting,” said Dr Arndt Vogel, Professor of Medicine at Hannover Medical School. “After many failures in the last 12 years, the combination of Tecentriq and Avastin shows improvement in overall survival compared to sorafenib and offers patients the opportunity for improved disease control with a high overall response rate.”

The approval is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in combination with Avastin reduced the risk of death (overall survival [OS]) by 42% (hazard ratio [HR]=0.58; 95% CI: 0.42–0.79; p=0.0006) and reduced the risk of disease worsening or death (progression-free survival [PFS]) by 41% (HR=0.59; 95% CI: 0.47–0.76; p<0.0001), compared with sorafenib. IMbrave150 is the first Phase III cancer immunotherapy study to show an improvement in both OS and PFS in people with unresectable HCC compared with sorafenib. Grade 3–4 adverse events occurred in 57% of people receiving Tecentriq and Avastin and 55% of people receiving sorafenib. The most frequent serious adverse reactions for the combination (≥2%) were bleeding in the gastrointestinal tract and fever. These results were published in the New England Journal of Medicine on 14 May 2020.

Today’s approval follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2020. In May 2020, the US Food and Drug Administration approved Tecentriq in combination with Avastin for the treatment of people with unresectable or metastatic HCC who have not received prior systemic therapy. In addition, in October 2020 the China National Medical Products Administration approved the combination for the treatment of people with unresectable HCC who have not received prior systemic therapy. In total, the combination is now approved in 59 countries for people with unresectable HCC. Tecentriq in combination with Avastin was also recently included as

Read more

Cites Link to Nonalcoholic Fatty Liver Disease and Importance of Early Detection

Echosens, a high-technology company offering the FibroScan family of products, urges increased awareness of the rise of liver cancer rates, which have more than tripled since 1980, while death rates have more than doubled during this time. About 21,000 Americans are diagnosed with primary liver cancer each year—twice as common in men than in women. Risk factors include other liver diseases, including cirrhosis, chronic hepatitis B, chronic hepatitis C and non-alcoholic fatty liver disease (NAFLD). NAFLD may be a key driver of increased cancer associated with obesity, while non-alcoholic steatohepatitis (NASH) is the fastest growing cause of liver cancer among transplant candidates.

“People with NAFLD have higher rates of several types of cancer, with the greatest increase seen for liver cancer and other gastrointestinal cancers,” says Jon Gingrich, CEO, Echosens North America. “Point-of-care examinations, monitoring and ongoing assessment of liver fat and stiffness as provided by FibroScan, a rapid, non-invasive point of care examination, can identify individuals who are asymptomatic and undiagnosed for liver damage.”

Researchers have found that liver cancer, NAFLD, hepatitis C and liver transplants are prevalent in 40-80% of people who have Type 2 diabetes and in 30-90% of people who are obese. Being overweight or obese is responsible for about 85% of fatty liver disease.

“Approximately 30,000 people die from liver cancer each year and these numbers have continued to rise in recent years,” says Lynn Gardner Seim, Executive Vice President and Chief Operating Officer, American Liver Foundation. “It is essential that patients at risk for liver cancer, including those who have previously been diagnosed with hepatitis C, NAFLD, NASH and other liver diseases, talk with their doctors and have a plan in place for getting screened.”

Traditional approaches to assessing liver health, such as liver biopsy and advanced radiological imaging, may not be cost effective nor accessible to the broader at-risk population. FibroScan directly measures physical properties of stiffness and fat liver to provide reproducible results and allow for both diagnosis and monitoring of liver stiffness and liver fat. It is also recognized worldwide as the reference for non-invasive liver diagnosis supported with more than 2,000 medical publications and 40 guideline recommendations.

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. For more information, please visit http://www.echosens.us and follow us on Twitter (@echosensNA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005599/en/

Contacts

Media:
Brittany Tedesco
CPR Communications
[email protected]
201.641.1911 x 14

Source Article

Read more

Heal Your Liver With Eden Energy Medicine

Your liver is the largest physical organ in the body. It is involved in digestion, metabolism, storage and distribution of nourishment, filtration, detoxification, and immune function.

You'd think having short legs wouldn't be a problem. Less body to nourish and protect, right? But according to the online article, "The Ten Weirdest Clues to Your Body's Health," that's not the case!

"If your legs are on the stocky side, you may need to take better care of your liver. In a 2008 study, British researchers found that women with legs between 20 and 29 inches tended to have higher levels of four enzymes that indicate liver disease . Factors such as childhood nutrition may not only influence growth patterns, but also liver development well into adulthood, say researchers.

Prevent it: Avoid exposure to toxins your liver has to process, which will keep it healthier, longer. Wear a mask and gloves while cleaning or working with any type of harsh chemical. Limit alcohol intake to one 5-ounce glass of wine or 12-ounce bottle of beer daily. "

Eden Energy Medicine can be another easy way to support your Liver's health. Massaging your hands and feet on a daily basis will keep your liver strong and healthy. It's a lovely form of self-care as well, which can take place in a bubble bath, in bed, while watching a good movie or listening to good music. If you have a partner in your life, try trading foot and hand massages as a form of nurturing, nonsexual touch.

The acupuncture points on the feet that are most effective for keeping your liver clear are found at the "V" where the big toe meets the second toe on the top of the foot at the base of the metatarsal bridge. If nothing else, be sure to massage these "source points" of Liver chi several times a day.

Your liver is very important to hormonal health. If you have PMS, sedating Liver Meridian can help immensely with groin pain. The simplest way to sedate Liver Meridian is to lie down and place your fingertips where your legs attach to your body. Rest in this pose for two to three minutes.

You can also sedate your Liver Meridian by holding specific acupuncture points. This is known as acupressure and it is usually the most effective. Here's how:

1. Simultaneously place the middle finger of one hand on Liver 2 (inside of big toe where it meets the foot) and the other hand on Heart 8 (make a fist; see where the pinky touches the palm? That's Heart 8). Press in lightly. Hold for two minutes.

2. Repeat on the other side.

3. Then place the middle finger of one hand on Liver 4 (a little dip in front of the anklebone) and the middle finger of the other hand on Lung 8 (on the crease of the wrist just below the thumb).

Don't panic about pinpoint accuracy. Meridian points have a range of a dime to a quarter. …

Read more